Biological evaluation of medical devices - Part 7: Ethylene oxide sterilization residuals - Amendment 1: Applicability of allowable limits for neonates and infants (ISO 10993-7:2008/Amd 1:2019)

2021-12-09- JO-  the EN was submitted to FV wiith the link to the legislation (90/385/EEC, 93/42/EEC)
however since these legilsations have been repealed, the link has been removed and the EN is to proceed to publication

Biologische Beurteilung von Medizinprodukten - Teil 7: Ethylenoxid Sterilisationsrückstände - Änderung 1: Anwendbarkeit zulässiger Grenzwerte für Neugeborene und Kleinkinder (ISO 10993 7:2008/Amd 1:2019)

Évaluation biologique des dispositifs médicaux - Partie 7: Résidus de stérilisation à l'oxyde d'éthylène - Amendement 1 (ISO 10993-7:2008/Amd 1:2019)

Biološko ovrednotenje medicinskih pripomočkov - 7. del: Ostanki po sterilizaciji z etilenoksidom - Dopolnilo A1: Uporaba dovoljenih mejnih vrednosti za novorojenčke in dojenčke (ISO 10993-7:2008/Amd 1:2019)

General Information

Status
Published
Publication Date
11-Jan-2022
Withdrawal Date
30-Jul-2022
Current Stage
6060 - Definitive text made available (DAV) - Publishing
Start Date
12-Jan-2022
Completion Date
12-Jan-2022

Relations

Effective Date
14-Dec-2016
Effective Date
28-Jan-2023

Overview

EN ISO 10993-7:2008/A1:2022 is an essential European standard addressing the biological evaluation of medical devices, specifically focusing on ethylene oxide (EO) sterilization residuals. This amendment clarifies the applicability of allowable EO residual limits for neonates and infants, ensuring safer use of sterilized medical devices in vulnerable patient populations. It updates thresholds based on patient body mass and exposure risk, enhancing compliance with modern safety requirements.

Developed collaboratively by ISO Technical Committee ISO/TC 194 and CEN/TC 206, this amendment replaces references to now-repealed European legislation and must be adopted by all CEN members by July 2022. It ensures harmonization of sterilization residual evaluation with biological risk management processes for medical devices used across all age groups.

Key Topics

  • Ethylene Oxide Residuals
    Definition and regulation of EO residues and ethylene chlorohydrin (ECH) in sterilized medical devices.

  • Exposure Categories
    Devices classified by exposure duration:

    • Limited exposure (A): Up to 24 hours
    • Prolonged exposure (B): More than 24 hours up to 30 days
    • Permanent exposure (C): More than 30 days or lifetime contact
  • Allowable Limits for Neonates and Infants
    Special patient populations require adjusted EO and ECH limits based on body weight and toxicity indices:

    • Neonates and infants have lower allowable residual thresholds due to increased sensitivity.
  • Concomitant and Proportional Exposure Factors
    Considerations when multiple devices are used simultaneously or devices are used for partial exposure durations, allowing adjustments to residue limits.

  • Analytical Methods and Validation
    Guidance on measuring EO and ECH residues, emphasizing validated extraction procedures and analytical techniques aligned with international validation guidelines (e.g., ICH Q2 (R2)).

  • Normative References and Bibliography
    Incorporates updated references like ISO 10993-1:2018 for biological evaluation, ISO 11135:2014 for EO sterilization process validation, and recognized validation frameworks ensuring scientific rigour.

Applications

This standard is critical for manufacturers, regulators, and testing laboratories involved with:

  • Medical Device Sterilization
    Ensuring EO sterilization protocols do not exceed residual contamination limits that could harm patients, particularly neonates and infants.

  • Device Risk Management
    Incorporating EO residue assessments into overall biological risk management strategies, conforming to ISO 10993-1 and related standards.

  • Pediatric Medical Devices
    Designing and validating sterilization processes and residual testing with appropriate limits for sensitive populations such as premature neonates, full-term neonates, and infants.

  • Regulatory Compliance
    Meeting European harmonized standards and supporting market access by complying with updated CEN requirements.

  • Clinical Safety Evaluations
    Performing targeted risk assessments on EO sterilized devices used in intensive care, neonatal units, or pediatric applications.

Related Standards

EN ISO 10993-7:2008/A1:2022 works within the framework of several related standards, including:

  • ISO 10993 Series
    Biological evaluation of medical devices covering general principles, cytotoxicity, sensitization, and systemic toxicity.

  • ISO 10993-1:2018
    Fundamental biological evaluation and testing methods informing EO residue risk assessment.

  • ISO 11135:2014
    Requirements for development and validation of EO sterilization processes.

  • ISO 10993-17
    Toxicological risk assessment principles used to derive EO residue limits, including concomitant exposure factors.

  • International Validation Guides
    ICH Q2 (R2), Eurachem, AOAC guidelines for analytical method validation relevant to residue testing.

Summary

EN ISO 10993-7:2008/A1:2022 amendment provides updated, science-based limits for EO sterilization residuals with particular emphasis on neonates and infants. It clarifies exposure categories, introduces population-specific dose thresholds, and promotes validated analytical methods, making it indispensable for ensuring the safety and regulatory compliance of EO-sterilized medical devices within pediatric care and broader clinical use. Adherence to this standard supports effective biological risk management and patient safety priorities in medical device manufacturing and evaluation.

Amendment

EN ISO 10993-7:2009/A1:2022

English language
11 pages
Preview
Preview
e-Library read for
1 day

Frequently Asked Questions

EN ISO 10993-7:2008/A1:2022 is a amendment published by the European Committee for Standardization (CEN). Its full title is "Biological evaluation of medical devices - Part 7: Ethylene oxide sterilization residuals - Amendment 1: Applicability of allowable limits for neonates and infants (ISO 10993-7:2008/Amd 1:2019)". This standard covers: 2021-12-09- JO- the EN was submitted to FV wiith the link to the legislation (90/385/EEC, 93/42/EEC) however since these legilsations have been repealed, the link has been removed and the EN is to proceed to publication

2021-12-09- JO- the EN was submitted to FV wiith the link to the legislation (90/385/EEC, 93/42/EEC) however since these legilsations have been repealed, the link has been removed and the EN is to proceed to publication

EN ISO 10993-7:2008/A1:2022 is classified under the following ICS (International Classification for Standards) categories: 11.100.20 - Biological evaluation of medical devices. The ICS classification helps identify the subject area and facilitates finding related standards.

EN ISO 10993-7:2008/A1:2022 has the following relationships with other standards: It is inter standard links to EN ISO 10993-7:2008, FprEN ISO 10993-7. Understanding these relationships helps ensure you are using the most current and applicable version of the standard.

EN ISO 10993-7:2008/A1:2022 is associated with the following European legislation: EU Directives/Regulations: 90/385/EEC, 93/42/EEC; Standardization Mandates: M/BC/CEN/89/9. When a standard is cited in the Official Journal of the European Union, products manufactured in conformity with it benefit from a presumption of conformity with the essential requirements of the corresponding EU directive or regulation.

You can purchase EN ISO 10993-7:2008/A1:2022 directly from iTeh Standards. The document is available in PDF format and is delivered instantly after payment. Add the standard to your cart and complete the secure checkout process. iTeh Standards is an authorized distributor of CEN standards.

Standards Content (Sample)


SLOVENSKI STANDARD
01-marec-2022
Biološko ovrednotenje medicinskih pripomočkov - 7. del: Ostanki po sterilizaciji z
etilenoksidom - Dopolnilo A1: Uporaba dovoljenih mejnih vrednosti za
novorojenčke in dojenčke (ISO 10993-7:2008/Amd 1:2019)
Biological evaluation of medical devices - Part 7: Ethylene oxide sterilization residuals -
Amendment 1: Applicability of allowable limits for neonates and infants (ISO 10993-
7:2008/Amd 1:2019)
Biologische Beurteilung von Medizinprodukten - Teil 7: Ethylenoxid-
Sterilisationsrückstände - Änderung 1 (ISO 10993-7:2008/Amd 1:2019)
Évaluation biologique des dispositifs médicaux - Partie 7: Résidus de stérilisation à
l'oxyde d'éthylène - Amendement 1 (ISO 10993-7:2008/Amd 1:2019)
Ta slovenski standard je istoveten z: EN ISO 10993-7:2008/A1:2022
ICS:
11.100.20 Biološko ovrednotenje Biological evaluation of
medicinskih pripomočkov medical devices
2003-01.Slovenski inštitut za standardizacijo. Razmnoževanje celote ali delov tega standarda ni dovoljeno.

EN ISO 10993-7:2008/A1
EUROPEAN STANDARD
NORME EUROPÉENNE
January 2022
EUROPÄISCHE NORM
ICS 11.100.20
English Version
Biological evaluation of medical devices - Part 7: Ethylene
oxide sterilization residuals - Amendment 1: Applicability
of allowable limits for neonates and infants (ISO 10993-
7:2008/Amd 1:2019)
Évaluation biologique des dispositifs médicaux - Partie Biologische Beurteilung von Medizinprodukten - Teil 7:
7: Résidus de stérilisation à l'oxyde d'éthylène - Ethylenoxid-Sterilisationsrückstände - Änderung 1
Amendement 1 (ISO 10993-7:2008/Amd 1:2019) (ISO 10993-7:2008/Amd 1:2019)
This amendment A1 modifies the European Standard EN ISO 10993-7:2008; it was approved by CEN on 5 November 2019.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for inclusion of
this amendment into the relevant national standard without any alteration. Up-to-date lists and bibliographical references
concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN
member.
This amendment exists in three official versions (English, French, German). A version in any other language made by translation
under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the
same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia,
Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway,
Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and
United Kingdom.
EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION

EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels
© 2022 CEN All rights of exploitation in any form and by any means reserved Ref. No. EN ISO 10993-7:2008/A1:2022 E
worldwide for CEN national Members.

Contents Page
European foreword . 3

European foreword
This document (EN ISO 10993-7:2008/A1:2022) has been prepared by Technical Committee ISO/TC
194 "Biological and clinical evaluation of medical devices" in collaboration with Technical Committee
CEN/TC 206 “Biological and clinical evaluation of medical devices” the secretariat of which is held by
DIN.
This Amendment to the European Standard EN ISO 10993-7:2008 shall be given the status of a national
standard, either by publication of an identical text or by endorsement, at the latest by July 2022, and
conflicting national standards shall be withdrawn at the latest by July 2022.
Attention is drawn to the possibility that some of the elements of this document may be the subject of
patent rights. CEN shall not be held responsible for identifying any or all such patent rights.
Any feedback and questions on this document should be directed to the users’ national standards
body/national committee. A complete listing of these bodies can be found on the CEN website.
According to the CEN-CENELEC Internal Regulations, the national standards organizations of the
following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria,
Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland,
Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of
North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the
United Kingdom.
Endorsement notice
The text of ISO 10993-7:2008/Amd 1:2019 has been approved by CEN as EN ISO 10993-
7:2008/A1:2022 without any modification.

INTERNATIONAL ISO
STANDARD 10993-7
Second edition
2008-10-15
AMENDMENT 1
2019-12
Biological evaluation of medical
devices —
Part 7:
Ethylene oxide sterilization residuals
AMENDMENT 1: Applicability of
allowable limits for neonates and infants
Reference number
ISO 10993-7:2008/Amd.1:2019(E)
©
ISO 2019
ISO 10993-7:2008/Amd.1:2019(E)

© ISO 2019
All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may
be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting
on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address
below or ISO’s member body in the country of the requester.
ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Fax: +41 22 749 09 47
Email: copyright@iso.org
Website: www.iso.org
Published in Switzerland
ii © ISO 2019 – All rights reserved

ISO 10993-7:2008/Amd.1:2019(E)

Foreword
ISO (the International Organization for Standardization) is a worldwide federation of national standards
bodies (ISO member bodies). The work of preparing International Standards is normally carried out
through ISO technical committees. Each member body interested in a subject for which a technical
committee has been established has the right to be represented on that committee. International
organizations, governmental and non-governmental, in liaison with ISO, also take part in the work.
ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of
electrotechnical standardization.
The procedures used to develop this document and those intended for its further maintenance are
described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the
different types of ISO documents should be noted. This document was drafted in accordance with the
editorial rules of the ISO/IEC Directives, Part 2 (see www .iso .org/ directives).
Attention is drawn to the possibility that some of the elements of this document may be the subject of
patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of
any patent rights identified during the development of the document will be in the Introduction and/or
on the ISO list of patent declarations received (see www .iso .org/ patents).
Any trade name used in this document is information given for the convenience of users and does not
constitute an endorsement.
For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and
expressions related to conformity assessment, as well as information about ISO's adherence to the
World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see www .iso .org/
iso/ foreword .html.
This document was prepared by Technical Committee ISO/TC 194, Biological and clinical evaluation of
medical devices.
A list of all parts in the ISO 10993 series can be found on the ISO website.
Any feedback or questions on this document should be directed to the user’s national standards body. A
complete listing of these bodies can be found at www .iso .org/ members .html.
SIST EN ISO 10993
...

Questions, Comments and Discussion

Ask us and Technical Secretary will try to provide an answer. You can facilitate discussion about the standard in here.

Loading comments...

The EN ISO 10993-7:2008/A1:2022 standard serves as a crucial framework for the biological evaluation of medical devices, specifically addressing the concerns surrounding ethylene oxide (EO) sterilization residuals. Its scope explicitly includes the amendment of applicable allowable limits for neonates and infants, underscoring the importance of safety and biocompatibility for this vulnerable population. One of the primary strengths of this standard is its focus on defined exposure limits which are vital for ensuring that medical devices used on neonates and infants do not pose health risks due to EO residues. By clearly outlining these limits, the standard enhances the reliability of sterilization methods utilized in the production of medical devices, reaffirming a commitment to patient safety and regulatory compliance. Additionally, the amendment reflects the standard's adaptability to evolving medical practices and regulatory landscapes. As demonstrated by the recent updates that remove outdated legislation links, the standard remains relevant and is aligned with contemporary legal frameworks. This ensures that manufacturers and stakeholders in the medical device sector can rely on up-to-date guidelines that respond effectively to current industry needs. The incorporation of specific considerations for neonates and infants further highlights the standard’s relevance in pediatric medicine, where the tolerability of residuals is of utmost importance given the unique physiological characteristics of this demographic. The careful delineation of allowable limits aids in fostering the safe design and evaluation of pediatric medical devices. Overall, the EN ISO 10993-7:2008/A1:2022 standard not only provides essential guidelines for the assessment of EO sterilization residuals but also reinforces the commitment to protecting patient health, particularly for the most at-risk groups within the healthcare system. Its strengths in clarity, adaptability, and focus on vulnerable populations ensure its critical role in guiding biocompatibility assessments in the medical device industry.

EN ISO 10993-7:2008/A1:2022 표준은 의료 기기의 생물학적 평가에 관한 중요한 지침을 제공하며, 특히 에틸렌 산화물 살균 잔여물과 관련된 규정을 다루고 있습니다. 이 표준의 주요 강점은 신생아와 영아를 위한 허용 한계의 적용 가능성을 명확히 하였다는 점입니다. 이러한 세부사항은 의료 기기의 안전성을 높이고, 임상 환경에서의 생물학적 안전성을 보장하는 데 필수적입니다. 이 문서는 2021년 12월 9일에 제출된 EN의 개정안으로서, 이전의 EU 지침(90/385/EEC, 93/42/EEC)이 폐지됨에 따라 링크가 제거된 점도 주목할 필요가 있습니다. 그럼에도 불구하고, 표준은 계속해서 공표되는 절차를 진행 중이며, 이는 의료 기기 제조업체와 사용자가 에틸렌 산화물이 신생아와 영아에게 미치는 영향을 이해하고, 적절한 안전 기준을 따르게 하는 데 매우 중요합니다. 이 표준은 의료 기기의 설계와 평가 과정에 있어서 필수적인 요소로, 생물학적 반응을 고려한 임상 기초를 제공합니다. 전반적으로 EN ISO 10993-7:2008/A1:2022 표준은 의료 기기의 생물학적 안전성에 관한 체계적이고도 신뢰할 수 있는 가이드를 제공하여, 관련 업계에 크나큰 도움이 될 것입니다.

EN ISO 10993-7:2008/A1:2022の標準は、医療機器の生物学的評価に関する重要な文書であり、特にエチレンオキシド滅菌残渣に焦点を当てています。この修正案の目的は、新生児および幼児に対する許容限界の適用に関するものであり、医療機器の安全性を高めるための指針を提供しています。 この標準の範囲は、エチレンオキシドを使用した滅菌プロセスに関連する残留物の評価を行い、新生児や幼児に特有のリスクを考慮に入れる点で、特に有意義です。これにより、特に脆弱な患者群に対する影響を軽減し、安全性が確保されることが期待されます。 強みとしては、EN ISO 10993-7の体系的なアプローチが挙げられます。この標準は、科学的根拠に基づき、リスク評価のフレームワークを提供することで、製品開発者や規制当局にとって非常に有用です。さらに、新生児と幼児の健康を守るために、具体的なガイドラインを明確に示している点は、特に評価に値します。 この標準の関連性は高く、医療機器の安全性評価において不可欠な役割を果たしています。過去の法令(90/385/EEC、93/42/EEC)が廃止された後も、標準は引き続き重要な基準としての地位を保持しており、医療機器の開発における最新の要求に応えていることが示されています。このような標準に従うことで、医療機器の設計と製造プロセスにおいて生物学的安全性が確保され、患者の安心を提供するための基盤が築かれます。